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Introduction {#sec1}
============

Respiratory syncytial virus (RSV) infection can cause severe bronchiolitis in infants, often requiring hospitalization. RSV infection is one of the major causes of morbidity and mortality in early life worldwide, and the elderly and immunocompromised patients are at high risk for RSV-induced pneumonia ([@bib11]; [@bib17]; [@bib20]; [@bib29]; [@bib44]; [@bib46]; [@bib51]; [@bib52]; [@bib58]; [@bib60]). RSV primarily infects lung epithelial cells, which includes both proximal and distal airways as well as alveolar epithelial cells ([@bib9]; [@bib13]; [@bib19]; [@bib26]; [@bib29]; [@bib40]; [@bib48]; [@bib52]; [@bib62]). The infection is often characterized by epithelial sloughing, thick mucus secretion, and neutrophil infiltration ([@bib24]; [@bib40]; [@bib45]; [@bib52]; [@bib55]). Currently, no effective vaccine is available against RSV infection, and passive immunoprophylaxis using RSV-specific antibodies is expensive and only used in high-risk subjects ([@bib1]; [@bib60]; [@bib63]). Therefore, alternative strategies are needed to defend against this common pathogen.

Interleukin-22 (IL-22), a cytokine belonging to the IL-10 family, is produced by γδ T cells, T helper (Th) 17 cells, NKT cells, and innate lymphoid cells (ILC2, ILC3) ([@bib64]). IL-22 primarily acts on non-hematopoietic epithelial and stromal cells and plays a critical role in protecting mucosal epithelial-barrier functions and promoting tissue regeneration along with host defense against various pathogens ([@bib2]; [@bib8]; [@bib15]; [@bib56]; [@bib68]; [@bib74]). Indeed, the protective role of IL-22 in bacterial and fungal infections is well documented ([@bib2]; [@bib68]), although its function in the context of viral infections is not uniformly beneficial.

IL-22 has been shown to regulate rotavirus infection in synergy with IL-18 ([@bib76]) or interferon (IFN)-λ ([@bib25]). IL-22 plays a protective role during murine cytomegalovirus infection by coordinating anti-viral neutrophil infiltration into the infected tissue via induction of neutrophil-recruiting CXCL1 ([@bib66]). Loss of IL-22-producing CD4^+^ T cells during chronic HIV infection has been associated with increased damage to the gut epithelium associated with increased microbial translocation ([@bib31]). In addition to restricting viral replication, IL-22 has been reported to provide protection against virus-induced pathology in reducing tissue damage and inflammation ([@bib18]; [@bib22]; [@bib23]; [@bib27]; [@bib36]; [@bib54]; [@bib56]). However, in certain contexts, IL-22 has been shown to have detrimental effects during virus infection leading to exacerbated pathology, enhanced inflammation, tissue damage, and mortality ([@bib72]; [@bib77]). Moreover, increased levels of IL-22 in serum samples indicate poor prognosis for patients with HCV-associated hepatocellular carcinoma ([@bib71]). Therefore the effect of IL-22 on virus infection may depend on cellular and tissue contexts, as also the specific pathogen.

In a previous study, IL-22-deficient mice were found to exhibit exacerbated lung injury with impaired lung function compared with wild-type mice suggesting that IL-22 plays a protective role and promotes tissue repair in response to influenza infection ([@bib56]). Taken together, although various studies showed that IL-22 has epithelial-protective effects in mucosal tissue, given that there is limited information about the effect of IL-22 on RSV production in lung epithelial cells or in the lung, we tested the possibility that use of exogenous IL-22 as a treatment modality would limit RSV production, offering a novel approach to restrict this virus for which no vaccine is currently available. Here we show the ability of IL-22 to suppress RSV production in primary human airway epithelial cells (AECs) and *in vivo* in newborn mice. Our findings establish a previously unrecognized anti-viral effect of IL-22 that restores cellular autophagy.

Results {#sec2}
=======

Interleukin-22 (IL-22) Inhibits RSV Production in Human Airway Epithelial Cells and Mouse Lungs {#sec2.1}
-----------------------------------------------------------------------------------------------

To study the effect of IL-22 on virus production, primary human AECs established in air-liquid interface (ALI) cultures were infected with RSV line 19 strain (denoted here as RSV) ([@bib41]) and treated with or without recombinant human IL-22 (rhIL-22; denoted here as IL-22). We observed a 50%--80% reduction in viral plaque formation 48 h after IL-22-treatment of ALI cultures established from six independent subjects ([Figure 1](#fig1){ref-type="fig"}A). We next asked whether IL-22 impacted the life cycle of the virus early after infection. As expression of the L-polymerase gene of RSV was similar in both the IL-22-treated and IL-22-untreated groups at 24 and 48 h after RSV infection ([Figure 1](#fig1){ref-type="fig"}B), IL-22 did not appear to inhibit the ability of RSV to initiate early events required for its replication. IL-22 functions through a heterodimeric transmembrane receptor complex, which includes IL-22RA1 and IL-10RB ([@bib34]). The expression of the IL-22RA1 chain has been associated with IL-22 activity on the target cell ([@bib30]; [@bib73]). We observed that steady-state mRNA levels of both *IL22RA1* and *IL10RB* were similar across the different primary AECs and remained unaltered after RSV infection or IL-22 treatment at different time points ([Figure S1](#mmc1){ref-type="supplementary-material"}A) suggesting that the expression of the receptor subunits was similar in the established AECs. Similar to investigations of the effect of IL-22 on virus production in primary AECs, we also studied the effect of IL-22 on other RSV-infected epithelial cell lines, including A549. In line with the data derived from primary AECs, RSV viral load decreased after IL-22 treatment of A549 ([Figure 1](#fig1){ref-type="fig"}C) cells, with the cells showing unaltered RSV L-polymerase mRNA expression ([Figure 1](#fig1){ref-type="fig"}D). At the same time, expression of the IL-22 receptor subunits did not change after RSV infection or IL-22 treatment of A549 cells as observed in the case of primary AECs ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1IL-22 Inhibits RSV Production in Human Airway Epithelial Cells and Mouse Lungs(A) Representative viral plaques (left) generated from RSV-infected primary AECs from six independent subjects. At 2 h after infection with RSV (MOI of 1), the cells were treated with rh IL-22 (50 ng/mL) or left untreated and virus was detected by plaque assay using NY3.2 STAT1^−/−^ fibroblast cells. Percent viral titer (right) shown for the six independent primary AEC samples. The red line represents average viral titer in response to IL-22. Viral load with RSV alone considered as 100%. ∗∗p \< 0.01.(B) *RSV-L polymerase* expression in primary AECs of the human subjects measured by quantitative RT-PCR at 24 and 48 h after RSV infection ± IL-22 treatment. Data shown are mean ± SEM of six independent subjects. ns, non-significant.(C) Representative viral plaques (left) generated from A549 cells infected with RSV ± IL-22 at 24 h p.i., detected by plaque assay using NY3.2 STAT1^−/−^ fibroblast cells. Infection and IL-22 treatment was as described for primary AECs. Quantitation shown in percentages (right), where viral titer for RSV alone is considered as 100% for each individual experiment at each time point. Data shown are mean ± SEM of 3 independent experiments. ∗∗∗p \< 0.001.(D) *RSV-L polymerase* expression in A549 cells measured by quantitative RT-PCR at 24 and 48 h after RSV infection ± IL-22 treatment. Data shown are mean ± SEM of 3 independent experiments. ns, non-significant.(E) *RSV-L polymerase* expression in total lungs of neonatal mice measured by quantitative RT-PCR on days 1, 4, and 8 after RSV infection. Representative data shown are mean ± SEM of 3 independent experiments, n = 3--4 mice per group per experiment. ∗p \< 0.05, ∗∗p \< 0.01, ns, non-significant.(F) Representative viral plaques (left) and quantitated viral load (right) in total lungs of 5-day-old neonatal mice. Infected pups were treated i.p. with 5 μg IL-22Fc fusion protein on day 3 p.i. The lungs were harvested on days 6 and 8 p.i. to assay viral load by plaque assay using Vero cells. Representative data shown are mean ± SEM of 3 independent experiments, n = 4--5 mice per group per experiment. ∗∗∗∗p \< 0.0001, ns, non-significant.(G) Quantitative viral load in the lungs of 5-day-old neonatal mice (wild-type and IL-22^−/−^). Infected pups were treated i.p. with 5 μg IL-22Fc fusion protein on day 3 p.i. The lungs were harvested on day 6 p.i. to assay viral load by plaque assay using Vero cells. Data shown are mean ± SEM pooled from 3 independent experiments, n = 3--5 mice per group per experiment. ∗∗∗∗p \< 0.0001, ns, non-significant.For statistical analysis, groups were compared using Mann-Whitney test (A) and one-way ANOVA with Tukey post-hoc test (B--G). See [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

The cytokine IL-17A can regulate IL-22 function through common downstream pathways ([@bib65]). Therefore, we examined whether IL-17A rendered a similar anti-viral response against RSV in A549 cells. Interestingly, unlike IL-22, IL-17A was unable to suppress virus production in A549 cells. However, IL-22 and IL-17A co-treatment suppressed viral production by approximately 60%, similar to IL-22 treatment alone ([Figure S1](#mmc1){ref-type="supplementary-material"}C), showing that the anti-viral response by IL-22 against RSV is unaltered by, and independent of, the IL-17A response. We also asked whether the effect of IL-22 in suppressing RSV production was broadly applicable to various RSV strains. We thus examined the effect of IL-22 against infection by RSV 2-20, a more virulent and pathogenic strain than RSV Line-19 ([@bib67]), and found that IL-22 treatment also significantly suppressed RSV 2-20 virus production in both primary AECs and A549 cells ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E), providing further evidence to support that IL-22 inhibits RSV production independent of viral strain and virulence.

Having found this effect of IL-22 on RSV infection of AECs occurs in *in vitro* settings, we next examined whether IL-22 treatment could decrease RSV production *in vivo* by treating neonatal RSV-infected mice intraperitoneally (i.p.) with human IL-22Fc fusion protein. The half-life of IL-22Fc in mice is about 107 h ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Also, as expected, whereas treatment with human IL-22Fc did not augment endogenous mouse *Il22* expression, it promoted expression of its target gene, *Reg3g* ([@bib78]), in the small intestine of the mice demonstrating an expected functional outcome of IL-22Fc treatment ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). IgG used as a control did not induce this effect ([Figure S2](#mmc1){ref-type="supplementary-material"}B). As shown in [Figure 1](#fig1){ref-type="fig"}E, the time course of RSV L-polymerase gene expression in mouse lungs showed continued increase until day 4 post-infection (p.i.) with decrease thereafter until day 8, most likely due to gradual viral clearance. Also, our immunostaining data suggested that the peak of the viral titer is reached within 4--6 days after infection (not shown). Taking these observations into consideration, i.p. IL-22Fc treatment was initiated on day 3 p.i. and the viral load was assayed twice on days 6 and 8 after infection. As control IgG did not display effects similar to IL-22 ([Figure S2](#mmc1){ref-type="supplementary-material"}B), we used PBS as a control in these experiments. As shown in [Figure 1](#fig1){ref-type="fig"}F, IL-22Fc treatment significantly decreased RSV titer in the lungs of the newborn mice on day 6 p.i. and it also did not render a delayed peak of viral load due to the treatment as suggested from the viral titer on day 8 p.i. We also examined the impact of IL-22Fc on viral infection in the absence of endogenous IL-22 using IL-22^−/−^ mice. The results showed similar viral load in RSV-infected wild-type and IL-22^−/−^ mice and also similar response to IL-22Fc treatment in the two groups ([Figure 1](#fig1){ref-type="fig"}G). These data suggest that endogenous IL-22 does not play a role in limiting virus production but that IL-22 can be used as a treatment modality to reduce viral load. Taken together, these findings strongly suggest a potential anti-viral role of IL-22 in the context of RSV infection both *in vitro* and *in vivo*.

IL-22 Prevents RSV Production through STAT3 Activation {#sec2.2}
------------------------------------------------------

Downstream of IL-22 signaling, IL-22 primarily activates STAT3 ([@bib4]; [@bib16]; [@bib21]; [@bib42]; [@bib73]) with STAT1 involvement in certain instances ([@bib37]). To determine which of these pathways is involved in the inhibition of virus production by IL-22, we examined STAT1 and STAT3 activation status in the IL-22-treated A549 cells and observed that IL-22 triggered phosphorylation of both STAT1 and STAT3 to similar degrees ([Figures 2](#fig2){ref-type="fig"}A and 2B). To next determine which STAT pathway was necessary for the inhibitory effect of IL-22 on RSV production, we treated RSV-infected cells with the STAT1- and STAT3-specific inhibitors fludarabine and sunitinib, respectively ([Figures 2](#fig2){ref-type="fig"}C and 2D), in the presence or absence of IL-22. Blockade of STAT1 with fludarabine had no effect on the anti-viral effect of IL-22, whereas blocking STAT3 activation with sunitinib reversed the inhibitory effects of IL-22 ([Figure 2](#fig2){ref-type="fig"}E). Also, both inhibitors were ineffective in the absence of IL-22 ([Figure 2](#fig2){ref-type="fig"}E). These results collectively suggested that IL-22 suppresses RSV production through a downstream mechanism mediated by STAT3 activation.Figure 2IL-22 Inhibits RSV Production through STAT3 Activation, Independent of Downstream Interferon Signaling(A and B) Representative immunoblot (left) and quantitation (right) of (A) phospho-STAT1 (pSTAT1) and total-STAT1 (tSTAT1) and (B) phospho-STAT3 (pSTAT3) and total-STAT3 (tSTAT3) in A549 cells after RSV infection and 15 min post IL-22 treatment to detect STAT activation. Data shown are mean ± SEM of 3 independent experiments. ∗∗∗p \< 0.001, ns, non-significant.(C and D) Representative immunoblot (left) and quantitation (right) of (C) pSTAT1 and tSTAT1 and (D) pSTAT3 and tSTAT3 in A549 cells infected with RSV ± IL-22 and treated with or without fludarabine or sunitinib at 15 min post IL-22 treatment. Data shown are mean ± SEM of 3 independent experiments. ∗∗∗∗p \< 0.0001, ns, non-significant.(E) Representative viral plaques (left) generated from A549 cells infected with RSV ± IL-22 and treated with/without STAT inhibitors, fludarabine, or sunitinib at 24 h p.i. As described in legend to [Figure 1](#fig1){ref-type="fig"}, IL-22 was added 2 h after infection of cells. Quantitation shown in percentages (right), where viral titer for RSV alone considered as 100% for each individual experiment. Data shown are mean ± SEM of 3 independent experiments. ∗p \< 0.05, ∗∗∗p \< 0.001, ns, non-significant.For statistical analysis, groups were compared using one-way ANOVA with Tukey post-hoc test (A--E).

IL-22 Regulates RSV Production without Altering Expression of Type I and Type III Interferons {#sec2.3}
---------------------------------------------------------------------------------------------

Type I IFNs play a crucial role in host defense against viruses and upregulate several IFN-stimulated genes (ISGs) that play important roles in eliminating the virus from infected cells ([@bib4]; [@bib16]; [@bib42]). In addition, type III IFNs (IFN-λ) have been also implicated in anti-viral host defense ([@bib33]). Activation of both STAT1 and STAT3 has been demonstrated in target cells in response to type I and III IFNs ([@bib10]; [@bib33]; [@bib70]; [@bib75]). We, therefore, examined whether the anti-viral effects of IL-22 are mediated by increased expression of ISGs in the AECs. Surprisingly, we observed that IL-22 did not alter the gene expression of type I IFNs (IFN-α2 and IFN-β1) in six different primary AECs after 24 h of RSV infection ([Figure 3](#fig3){ref-type="fig"}A). We also observed that the release of both IFN-β and IFN-λ from RSV-infected A549 cells remained unaltered after IL-22 treatment ([Figure 3](#fig3){ref-type="fig"}B). We did not detect any IFNs in the culture medium collected from the basolateral surface of primary AECs. In addition, IL-22 did not cause any change in the expression of different ISGs (IFIT1, ISG15, and OASL) in the RSV-infected primary AECs as well as in A549 cells at 24 h after infection ([Figures 3](#fig3){ref-type="fig"}C and 3D). Taken together, these data showed that IL-22 inhibits RSV production in epithelial cells that is dependent on STAT3 activation, but it does not result in increased type I or type III IFN production.Figure 3IL-22 Treatment Does Not Alter Expression of Type I and Type III Interferons in RSV-Infected Epithelial Cells(A) mRNA expression of *IFNα2* (left) and *IFNβ1* (right) in primary AECs of the human subjects measured by quantitative RT-PCR at 24 h after RSV infection ± IL-22 treatment. Data shown are mean ± SEM of 6 independent subjects. ns, non-significant.(B) Protein expression corresponding to IFN-β (left) and IFN-λ (right) in A549 cells infected with RSV ± IL-22, detected by ELISA at 24 h p.i. Data shown are mean ± SEM from 2 independent experiments. ns, non-significant.(C and D) mRNA expressions of ISGs (*IFIT1*, *ISG15*, and *OASL*) in (C) primary AECs and (D) A549 cells measured by quantitative RT-PCR at the given time points p.i. Data shown are mean ± SEM of (C) 4 independent subjects and (D) 3 independent experiments. ns, non-significant.For statistical analysis, groups were compared using one-way ANOVA with Tukey post-hoc test (A--D). See [Figure S3](#mmc1){ref-type="supplementary-material"}.

RSV Infection Upregulates LC3B Expression and Then Hijacks the Autophagic Machinery by Co-localizing with LC3B Facilitating Virus Production {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------------------------

We next considered an alternate STAT3-mediated pathway downstream of IL-22 that could play a role in suppressing viral infection, which was cellular autophagy, a strategy that cells use in times of stress to recycle otherwise unusable cellular parts and that has been also shown to promote antiviral immunity. Indeed, viruses are known to subvert or hijack components of the autophagic machinery for their own survival benefit ([@bib5]; [@bib12]; [@bib28]; [@bib50]; [@bib61]). To determine whether RSV infection could impact cellular autophagy, we studied the expression of a key protein associated with the autophagic machinery in RSV-infected cells. During autophagy, a cytosolic form of the microtubule-associated protein 1A/1B-light chain 3B (LC3B-I) is conjugated to phosphatidylethanolamine to form a lipidated LC3-phosphatidylethanolamine conjugate (LC3B-II), which then associates with autophagosomal membranes and is considered a universal marker for the onset of autophagy ([@bib47]). Upon RSV infection of both primary AECs and A549 cells, we observed a significant increase in LC3B-II expression ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) showing that RSV infection could indeed have an effect on the cellular autophagic machinery.

To determine whether and how LC3B expression might be functionally influencing RSV infection of the epithelial cells, we knocked down LC3B expression by transfecting both primary AECs and A549 cells with dicer-substrate short interfering RNA (dsiRNA) against LC3B (dsiLC3B) or with a non-target negative control (NC) small interfering RNA (dsiNC1) (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). We effectively knocked down LC3B, as we observed an impressive increase in cellular LC3B-II levels at 48 h after RSV infection in control dsiNC1-transfected primary AECs or A549 cells, but not in cells transfected with dsiLC3B ([Figures 4](#fig4){ref-type="fig"}A and 4B). Importantly, this loss of LC3B also severely hampered RSV production ([Figures 4](#fig4){ref-type="fig"}C and 4D), suggesting that RSV requires the autophagic machinery for productive infection. This decreased viral load from the LC3B knocked down cells was also similar to IL-22-treated cells at 48 h after infection ([Figures 4](#fig4){ref-type="fig"}C and 4D), further correlating suppression of RSV infection by IL-22 with the autophagic pathway.Figure 4IL-22 Blocks Co-localization of RSV and LC3B(A and B) Representative immunoblot (left) and quantitation (right) for LC3B expression in dsiLC3B-transfected (A) primary AECs and (B) A549 cells after RSV infection. Data shown are mean ± SEM of 2 independent experiments.(C and D) Representative viral plaques (left) and quantitated viral titer (right) in dsiLC3B-transfected (C) primary AECs and (D) A549 cells after RSV infection and treated with/without IL-22. Percent viral titer for RSV-infected dsiNC1 control considered as 100% for each individual experiment. Data shown are mean ± SEM of 2 independent experiments.(E and F) Representative immunoblot (left) and quantitation (right) for LC3B expression in (E) primary AECs and (F) A549 cells after RSV ± IL-22 treatment. Data shown are mean ± SEM of 3 independent experiments. ns, non-significant.(G) Representative images of immunofluorescence staining of RSV (red), LC3B (green), and nuclei (blue) in A549 cells after RSV ± IL-22 treatment along with uninfected cells. The yellow spots (rightmost panel) show the LC3B puncta that are co-positive for RSV. Images were taken at 60× magnification, 1.4 numerical aperture. Scale bar, 10 μm.(H) Co-localization was assessed by determining the degree of overlap on a per pixel basis. RSV and LC3 emissions were first segmented based on intensity to generate a binary mask. Co-localization was determined using a binary "having" statement to identify LC3-positive puncta containing RSV. It was found that 72.1% of the total LC3 area was co-localized with RSV in the RSV-infected cells, whereas only 10.2% was co-localized with RSV in the RSV + IL-22-treated group.(I) Number of LC3B puncta normalized to the cell count in RSV and RSV ± IL-22-treated groups.Representative data shown are mean ± SEM of 3 independent experiments. ∗p \< 0.05, ns, non-significant.For statistical analysis, groups were compared using one-way ANOVA with Tukey post-hoc test (A--F) and Mann-Whitney test (G--I).

We next explored how RSV regulated the autophagic process through LC3B, and whether IL-22 might influence this process. We did not observe a significant difference in LC3B-II expression after IL-22 treatment in infected primary AECs and A549 cells ([Figures 4](#fig4){ref-type="fig"}E and 4F). Given that viruses have been shown to subvert LC3B for their propagation in infected cells ([@bib12]; [@bib28]; [@bib50]; [@bib61]), we next explored the possibility that RSV might associate with LC3B, which was compromised by IL-22. Confocal microscopy revealed that RSV particles indeed co-localized with LC3B in infected A549 cells and IL-22 treatment interfered with this process ([Figure 4](#fig4){ref-type="fig"}G); IL-22 was found to reduce RSV-LC3B co-localization by almost 7-fold ([Figures 4](#fig4){ref-type="fig"}G and 4H). It was found that 72.1% of the total LC3 area was co-localized with RSV in the RSV-infected cells, whereas only 10.2% was co-localized with RSV in the RSV + IL22-treated group ([Figure 4](#fig4){ref-type="fig"}H). Moreover, this imaging approach also showed a marked reduction in RSV signal in the presence of IL-22 in the infected cells, whereas the LC3B signal was largely maintained ([Figure 4](#fig4){ref-type="fig"}I), as also observed by immunoblotting ([Figures 4](#fig4){ref-type="fig"}E and 4F). Taken together, the data showed that IL-22 treatment does not suppress RSV-mediated increase in LC3B expression. Rather, IL-22 has the ability to disrupt LC3B-virus association.

RSV Inhibits Autophagy by Blocking Autophagosome-Lysosome Fusion, whereas IL-22 Promotes Cellular Autophagy in a STAT3-Dependent Manner {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------------------

To determine whether active autophagy was required for productive infection, we pre-treated A549 cells with an autophagic inhibitor, chloroquine (CQ), which raises lysosomal pH and inhibits autophagosome-lysosome fusion ([@bib43]), and then infected the cells with RSV. Comparing RSV-infected cells with RSV + CQ cells, we observed that blocking the process of autophagy with CQ did not impair viral production in any way ([Figure 5](#fig5){ref-type="fig"}A), suggesting that LC3B-II rather than the process of autophagy was important for virus production. We did, however, observe that CQ ablated IL-22-mediated suppression of RSV production ([Figure 5](#fig5){ref-type="fig"}A), showing that the ability of IL-22 to inhibit RSV production relies on maintenance of active cellular autophagy.Figure 5IL-22 Promotes Cellular Autophagy in a STAT3-Dependent Manner(A) Representative viral plaques (left) and quantitated percent viral titer (right) in RSV-infected A549 cells with/without IL-22 and/or chloroquine treatment. Percent viral titer for RSV alone considered as 100% for each individual experiment. Data shown are mean ± SEM of 3 independent experiments. ∗∗∗∗p \< 0.0001, ns, non-significant.(B) Representative images (left) of A549 cells transduced with tandem sensor RFP-GFP-LC3B baculoviral particles showing immunofluorescent autophagosomes (yellow puncta) and autolysosomes (red puncta) in the indicated treatment groups. Images taken at 60× magnification. Scale bar, 10 μm. Quantitation (right) performed using spot detection to identify puncta. Data shown are mean ± SEM of 2 independent experiments. ∗p \< 0.05, ns, non-significant.(C) Representative immunoblot (left) and quantitation (right) of p62 expression in A549 cells after RSV ± IL-22 treatment. Data shown are mean ± SEM of 3 independent experiments. ∗p \< 0.05, ∗∗∗p \< 0.001, ns, non-significant.(D) Representative immunoblot (top) and quantitation (bottom) of p62 expression in A549 cells infected with RSV ± IL-22 and treated with or without fludarabine or sunitinib. Data shown are mean ± SEM of 3 independent experiments. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001, ns, non-significant.For statistical analysis, groups were compared using one-way ANOVA with Tukey post-hoc test (A--D).

We further studied the impact of RSV on cellular autophagy and the effect of IL-22 on this process by monitoring the intracellular residence of LC3B. At the early stages of cellular autophagy, LC3B-II is recruited to autophagosomal membranes, triggering the onset of autophagy. Later, LC3B-II resides in autolysosomes formed by the fusion of autophagosomes and lysosomes, causing degradation of intra-autophagosomal components ([@bib47]). To determine whether RSV inhibited this process, we transduced A549 cells with a pH-sensitive tandem RFP-GFP-LC3B plasmid vector that monitors the formation of autolysosomes from autophagosomes. The acidic pH of autolysosomes causes selective degradation of the acid-sensitive GFP, but not RFP, and thus autophagosomes can be identified by yellow puncta (combined GFP + RFP signal), whereas autolysosomes can be identified by red puncta (RFP signal only). We transduced A549 cells with RFP-GFP-LC3B for 24 h, infected them with RSV, and followed with IL-22 treatment. To monitor baseline autophagic activity, a fraction of the transduced cells was not exposed to either RSV or IL-22. Compared with the uninfected condition, we observed that both RSV- and RSV + IL-22-treated cells had increased syncytia (multinucleated cells), a signature morphology for RSV infection, as visualized by nuclear staining ([Figure 5](#fig5){ref-type="fig"}B). Quantitation based on spot identification of yellow and red puncta revealed a significant decrease in autolysosome formation in RSV-infected cells compared with that in uninfected cells. Importantly, IL-22 treatment after RSV infection restored the basal level of autolysosomes and hence cellular autophagy in the infected cells ([Figure 5](#fig5){ref-type="fig"}B), showing that IL-22 can prevent RSV-mediated block in the formation of autolysosomes, which is essential to maintain cellular autophagy.

Taken together, the data showed that RSV infection initially triggers autophagosome formation but then subsequently blocks autophagosome fusion with lysosomes to prevent the formation of autolysosomes, which can be detrimental for viral survival. IL-22 can release viral control of autophagosomes and restore cellular autophagy. Although the imaging studies showed an increase in autolysosome formation in the presence of IL-22 in RSV-infected cells, it did not prove restoration of functional autophagy. We, therefore, assessed autophagic flux, which is a better index of autophagic activity ([@bib32]). The expression level of p62 (also called sequestosome 1 \[SQSTM1\]), a substrate degraded during active autophagy, is an accepted measure of autophagic flux in a cell ([@bib6]). p62 levels were examined by immunoblotting in the context of RSV infection in the presence or absence of IL-22. We observed that the level of p62 was significantly lower in RSV-infected A549 cells treated with IL-22 when compared with that in infected cells that were left untreated ([Figure 5](#fig5){ref-type="fig"}C). Thus, IL-22 did indeed restore autophagic flux in RSV-infected cells with concomitant reduction in RSV production, as shown in [Figures 1](#fig1){ref-type="fig"}A and 1C. Moreover, this IL-22-mediated promotion of autophagic flux (reduction in p62 levels) was blocked by sunitinib treatment ([Figure 5](#fig5){ref-type="fig"}D), which was consistent with the requirement for STAT3 activation in inhibition of RSV production, as depicted in [Figure 2](#fig2){ref-type="fig"}E.

Discussion {#sec3}
==========

The protective role of IL-22 in maintaining epithelial barrier integrity in the lung and the gut and in the induction of epithelial innate immunity in response to different pathogens is well established ([@bib2]; [@bib3]; [@bib64]). By demonstrating the ability of IL-22 to support cellular autophagy, our study provides a new insight into host defense functions of IL-22. We offer the following working model ([Figure 6](#fig6){ref-type="fig"}): RSV infection of lung epithelial cells first initiates the formation of autophagosomes in the epithelial cells but then blocks continuation/completion of the autophagic pathway by inhibiting autophagosome fusion with lysosomes through association with LC3B-II thereby preventing the formation of autolysosomes. This block at the autophagosome stage presumably provides a "safe space" in which to allow the virus to replicate and prevents the viral destruction that would normally occur in the acidic environment of the autolysosomes. IL-22 treatment, however, can prevent this blockade with restoration of autophagic flux, the net result being lower virus production.Figure 6Schematic of Working Model

Autophagy is important in multiple biological processes and plays a central role in cell survival during nutrient deprivation and infections ([@bib7]; [@bib14]; [@bib49]). The process of autophagy involves sequestration of cytosolic cargo, including damaged organelles, in autophagosomes that fuse with lysosomes to form autolysosomes in which the engulfed constituents undergo degradation and are released back for reuse by the cell. Recent studies show that this process provides antiviral immunity by causing degradation of viral proteins in infected cells ([@bib28]; [@bib38]). Antiviral effects of IL-22 have been previously appreciated, whereas the ability of IL-22 to reduce virus production from infected cells by promoting cellular autophagy has not been described heretofore. IL-22 was recently shown to be well tolerated in a Phase I clinical trial positioning the agent well for further trials to test efficacy in the control of inflammatory diseases ([@bib69]). Our findings suggest IL-22 as a therapeutic option in limiting RSV-induced illness in vulnerable populations because no effective vaccine against RSV is currently available.

Viruses are known to utilize autophagosomes as a replication niche ([@bib28]). Several viruses, especially picornaviruses, have been shown to hijack the cellular autophagic machinery for stabilization of its proteins and/or for viral replication ([@bib5]; [@bib12]; [@bib28]; [@bib50]; [@bib61]). Recently, another report associated RSV with autophagy in HEp-2 epithelial cells in which RSV replication was promoted by autophagy-mediated inhibition of apoptosis through an ROS-AMPK signaling axis ([@bib39]). We speculate that RSV inhibits macroautophagy rather than microautophagy or chaperone-mediated autophagy pathway ([@bib53]). One question that remains to be answered in further studies is precisely how RSV subverts LC3B to block autophagosome-lysosome fusion.

Our data suggest that the LC3B protein is co-opted for virus production, and during this process cellular autophagy is reduced in the infected cells as evident from increased levels of p62 in the cells. Also, blocking autophagy by CQ did not affect virus production showing that the process of autophagy per se is not required for virus production. Rather, promotion of autophagy by IL-22 is actually detrimental for virus production. However, it is important to note that we did not find any evidence of increased type I IFN or type III IFN production or increase in expression of ISGs in the infected cells in the presence of IL-22. In RSV-infected macrophages, autophagy-mediated increase in transforming growth factor-β production was shown to promote type I IFN production to limit virus production ([@bib57]). In a different study, infection of *LC3b*^--/--^ mice by RSV caused worse pathology and increased viral transcripts in the lungs ([@bib59]). As the viral titer in the lungs was not reported, it is unknown whether the increased inflammation and pathology were due to increased viral load, as suggested by our study. It is also possible that lack of LC3B did not cause productive infection but that accumulation of viral proteins in the absence of autophagy induced a pro-inflammatory response in the infected lungs. Taken in aggregate, functional autophagy supported by IL-22 confers host-protection.

Our observations bring to the fore another beneficial effect of IL-22 on host cells in addition to maintenance of barrier function and induction of defensins ([@bib2]; [@bib3]; [@bib64]). It is interesting that promotion of autophagy was dependent on STAT3, although IL-22 treatment activated both STAT1 and STAT3 in the AECs. This differs from the anti-viral role of IL-22 against rotavirus infection in the gut that is dependent on STAT1 activation and IFN-λ, a Type III IFN ([@bib25]). The mechanism by which IL-22-activated STAT3 promotes autophagy, whether involving nuclear or mitochondrial functions, remains to be determined in future studies. Taken together, these findings emphasize that the mechanisms underlying the protective effects of IL-22 are context and pathogen specific. As published by us previously, RSV infection in early life causes dysfunction of regulatory T cells and increases the risk for asthma in later life ([@bib35]). Limiting virus load with IL-22 may achieve the dual benefit of both stemming severity of illness in early life and reducing the risk for asthma in later life.

Limitations of the Study {#sec3.1}
------------------------

Our study demonstrates an anti-viral role of IL-22 that limits viral yield from infected airway and alveolar epithelial cells in culture and also in the lungs of newborn mice. Although we show that the anti-viral effect of IL-22 involves blockade of hijacking of the cellular autophagic machinery by RSV, the underlying mechanism remains to be elucidated. Also, the precise role of STAT3 in mediating the anti-viral effect of IL-22 needs further study.
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### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prabir Ray (<rayp@pitt.edu>).

### Materials Availability {#sec3.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec3.2.3}

All data are included in the published article and the [Supplemental Information](#appsec1){ref-type="fn"} files and any additional information will be available from the lead contact upon request.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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